CeriBell, Inc. (NASDAQ:CBLL) Receives $25.17 Average Target Price from Brokerages

Shares of CeriBell, Inc. (NASDAQ:CBLL) have received an average recommendation of “Moderate Buy” from the seven analysts that are currently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, five have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $25.1667.

A number of research analysts have recently weighed in on the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of CeriBell in a research report on Wednesday, October 8th. TD Cowen decreased their target price on shares of CeriBell from $36.00 to $20.00 and set a “buy” rating on the stock in a research note on Wednesday, November 5th. JPMorgan Chase & Co. dropped their price target on shares of CeriBell from $21.00 to $17.00 and set an “overweight” rating for the company in a research report on Wednesday, November 5th. Finally, Raymond James Financial began coverage on shares of CeriBell in a research report on Tuesday, October 21st. They set a “strong-buy” rating and a $19.00 price objective on the stock.

CeriBell Trading Up 4.9%

Shares of CBLL stock opened at $16.01 on Friday. The company has a debt-to-equity ratio of 0.12, a current ratio of 12.65 and a quick ratio of 12.25. The company has a market cap of $593.97 million and a price-to-earnings ratio of -10.60. CeriBell has a 1 year low of $10.01 and a 1 year high of $32.75. The firm has a fifty day moving average price of $12.42 and a 200-day moving average price of $14.34.

CeriBell (NASDAQ:CBLL) last released its earnings results on Tuesday, November 4th. The company reported ($0.37) earnings per share for the quarter, beating the consensus estimate of ($0.43) by $0.06. CeriBell had a negative return on equity of 29.63% and a negative net margin of 63.35%.The company had revenue of $22.59 million for the quarter, compared to the consensus estimate of $21.78 million. CeriBell has set its FY 2025 guidance at EPS. As a group, equities analysts predict that CeriBell will post -2.46 earnings per share for the current year.

Insider Buying and Selling

In other news, CTO Raymond Woo sold 11,112 shares of the business’s stock in a transaction dated Tuesday, November 11th. The stock was sold at an average price of $12.28, for a total value of $136,455.36. Following the transaction, the chief technology officer directly owned 167,704 shares in the company, valued at $2,059,405.12. The trade was a 6.21% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders sold 23,090 shares of company stock worth $285,941 over the last quarter. 20.10% of the stock is owned by company insiders.

Institutional Trading of CeriBell

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Bank of New York Mellon Corp lifted its holdings in CeriBell by 42.3% in the 1st quarter. Bank of New York Mellon Corp now owns 34,542 shares of the company’s stock worth $664,000 after purchasing an additional 10,268 shares in the last quarter. New York State Common Retirement Fund purchased a new position in shares of CeriBell in the first quarter worth $67,000. KLP Kapitalforvaltning AS purchased a new position in shares of CeriBell in the first quarter worth $36,000. Federated Hermes Inc. grew its stake in CeriBell by 111.3% during the first quarter. Federated Hermes Inc. now owns 786,751 shares of the company’s stock valued at $15,113,000 after acquiring an additional 414,500 shares in the last quarter. Finally, Deutsche Bank AG increased its holdings in CeriBell by 0.4% in the 1st quarter. Deutsche Bank AG now owns 231,629 shares of the company’s stock valued at $4,450,000 after acquiring an additional 842 shares during the last quarter.

CeriBell Company Profile

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.